Skip to main content
S&P 5007,367.69-4.17%DOW51,587.07-3.32%NASDAQ24,364.18-5.33%BTC$76,014.00-5.19%ETH$2,247.70-6.96%GOLD$4,114.90+1.03%OIL$90.13+2.28%
Smart Investors Daily
SID Premium
ES

NASDAQ · ESLAW

Estrella Immunopharma, Inc.

Healthcare · Biotechnology

$0.08

Up+$0.01 (+14.12%)

Updated Nov 5, 2026, 6:59 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.92M
P/E ratio
-5.57
Dividend yield
0.00%
52-week range
$0.05 – $0.14
Volume
1.29K
Avg. volume
13.88K

Price performance · ESLAW

ESLAW price history

1M range · 7 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ESLAW closed at $0.08 after 7 trading sessions, down 1.60% for the selected period.

Last close
$0.08
Period change
-1.60%
Period low
$0.06
Period high
$0.08
Daily close
View OHLC price history
ESLAW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$0.08$0.08$0.0799$0.07991.29K
Oct 29, 2026$0.07$0.0701$0.07$0.07014.3K
Oct 28, 2026$0.07$0.08$0.07$0.0712.1K
Oct 23, 2026$0.0799$0.08$0.07$0.079915.12K
Oct 22, 2026$0.067$0.0682$0.067$0.06821.11K
Oct 20, 2026$0.0526$0.061$0.0526$0.0611.29K
Oct 19, 2026$0.0812$0.0812$0.0812$0.0812500

Latest ESLAW news

The latest Smart Investors Daily articles mentioning ESLAW.

Stock researchCompany · Overview

ESLAW research

Overview

Company profile and research snapshot.

Company profile

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors

EMERYVILLE, Calif., October 26, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS® T-cell therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Cynthia Pussinen as Chief Executive Officer and Chairperson of its Board of Directors, effective October 25, 2026. Ms. Pussinen succeeds Cheng Liu, Ph.D., as Chief Executive Officer. Dr. Liu has been appo

Yahoo · Oct 15, 2026

Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase

EMERYVILLE, Calif., October 15, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced that the first patient who received two infusions, each at 5 × 10⁶ EB103 T cells/kg, three weeks apart, in the dose-expansion phase has tolerated the study drug well in the first month, with no treatment-related serious advers

Yahoo · Oct 14, 2026

Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

EMERYVILLE, Calif., October 14, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the activation of a fifth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating its investigational product candidate EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed

Yahoo · Aug 26, 2026

ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial

By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update STARLIGHT I Dose Expansion Underway Estrella Immunopharma (NASDAQ: ESLA) is currently conducting the Phase 1/2 STARLIGHT-1 trial of EB103 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). The company recently announced that the first patient was dosed in the expansion phase, following

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By